World Library  
Flag as Inappropriate
Email this Article

Granulomatosis with polyangiitis

Article Id: WHEBN0000794996
Reproduction Date:

Title: Granulomatosis with polyangiitis  
Author: World Heritage Encyclopedia
Language: English
Subject: Saddle nose, Retinal vasculitis, Arthritis, Nephrology, Hemoptysis
Collection: Arthritis, Autoimmune Diseases, Disorders of Fascia, Lung Disorders, Nephrology, Rheumatology, Systemic Connective Tissue Disorders, Vascular-Related Cutaneous Conditions
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Granulomatosis with polyangiitis

Granulomatosis with polyangiitis
Micrograph showing features characteristic of granulomatosis with polyangiitis - a vasculitis and granulomas with multi-nucleated giant cells. H&E stain.
Classification and external resources
ICD-10 M31.3
ICD-9-CM 446.4
DiseasesDB 14057
MedlinePlus 000135
eMedicine med/2401
MeSH D014890

Granulomatosis with polyangiitis (GPA), also known as Wegener's granulomatosis (WG), is a systemic disorder that involves both lungs and kidneys can be fatal. It requires long-term immunosuppression.[1] When referred to as Wegener's granulomatosis, it is named after Friedrich Wegener, who described the disease in 1936.[2] As a response to Wegener's association with the German Nazi party, professional bodies and journals have replaced his name with a descriptive name.[3][4] However, the older name is still often seen.

Granulomatosis with polyangiitis is part of a larger group of vasculitic syndromes called systemic vasculitides or necrotizing vasculopathies, all of which feature an autoimmune attack by an abnormal type of circulating antibody termed ANCAs (antineutrophil cytoplasmic antibodies) against small and medium-size blood vessels. Apart from GPA, this category includes Churg–Strauss syndrome and microscopic polyangiitis.[1] Although GPA affects small- and medium-size vessels,[5] it is formally classified as one of the small vessel vasculitides in the Chapel Hill system.[6][7]

Contents

  • Signs and symptoms 1
  • Causes 2
  • Pathophysiology 3
  • Diagnosis 4
    • Criteria 4.1
  • Treatment 5
  • Prognosis 6
  • Epidemiology 7
  • History 8
  • See also 9
  • References 10
  • External links 11

Signs and symptoms

Saddle nose due to granulomatosis with polyangiitis[8]
Lateral view of the face[8]

Initial signs are extremely variable, and diagnosis can be severely delayed due to the nonspecific nature of the symptoms. In general, rhinitis is the first sign in most people.[1][9]

Causes

Its causes are unknown, although microbes, such as bacteria and viruses, as well as genetics have been implicated in its pathogenesis.[9][10]

Pathophysiology


  • Classification criteria by the American College of Rheumatology

External links

  1. ^ a b c d e f g h i Seo P, Stone JH (July 2004). "The antineutrophil cytoplasmic antibody-associated vasculitides". Am. J. Med. 117 (1): 39–50.  
  2. ^ a b synd/2823 at Who Named It?
  3. ^ a b Falk RJ, Gross WL, Guillevin L, et al. (2011). "Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis". Ann. Rheum. Dis. 70: 74.  
  4. ^ Jennette JC (October 2013). "Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides". Clin Exp Nephrol 17 (5): 603–6.  
  5. ^ Gota, CE (May 2013). "Granulomatosis with Polyangiitis (GPA): Vasculitis". Merck Manual Professional. Merck Sharp & Dohme Corp. Retrieved 16 March 2014. 
  6. ^ Silva, Fred; Jennette, J. Charles; Heptinstall, Robert H.; Olson, Jean T.; Schwartz, Melvin (2007). Hepinstall's pathology of the kidney. Hagerstwon, MD: Lippincott Williams & Wilkins. p. 677.  
  7. ^ Ottoman BAE: Strawberry gingivitis of Wegener’s granulomatosis: A clinicopathological and immunohistochemical study and review of literature.Contemporary Journal immunology: Vol. 2 No. 1 pp. 59-67)
  8. ^ a b Kawabata, Simone Cristina; Hotta, Patricia Tiemy Hirono; Dias, Reinaldo Brito e; Mattos, Beatriz Silva Camara (2014). "Wegener Granulomatosis: Case Report of Facial Prosthetic Rehabilitation". Journal of Medical Cases 5 (12): 646–649.  
  9. ^ a b c d e Berden, A; Göçeroglu, A; Jayne, D; Luqmani, R; Rasmussen, N; Bruijn, JA; Bajema, I (January 2012). "Diagnosis and management of ANCA associated vasculitis.". BMJ 344: e26.  
  10. ^ Tracy, CL; Papadopoulos, PJ; Bye, MR; Connolly, H; Goldberg, E; O'Brian, RJ; Sharma, GD; Talavera, F; Toder, DS; Valentini, RP; Windle, ML; Wolf, RE (10 February 2014). Diamond, HS, ed. "Granulomatosis with Polyangiitis". Medscape Reference. WebMD. Retrieved 16 March 2014. 
  11. ^ van der Woude FJ, Rasmussen N, Lobatto S, et al. (February 1985). "Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis". Lancet 1 (8426): 425–9.  
  12. ^ Leavitt RY, Fauci AS, Bloch DA, et al. (August 1990). "The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis". Arthritis Rheum. 33 (8): 1101–7.  
  13. ^ Jennette JC, Falk RJ, Andrassy K, et al. (February 1994). "Nomenclature of systemic vasculitides. Proposal of an international consensus conference". Arthritis Rheum. 37 (2): 187–92.  
  14. ^ Bruce IN, Bell AL (April 1997). "A comparison of two nomenclature systems for primary systemic vasculitis". Br. J. Rheumatol. 36 (4): 453–8.  
  15. ^ a b c Tracy, CL; Papadopoulos, PJ; Bye, MR; Connolly, H; Goldberg, E; O'Brian, RJ; Sharma, GD; Talavera, F; Toder, DS; Valentini, RP; Windle, ML; Wolf, RE (10 February 2014). Diamond, HS, ed. "Granulomatosis with Polyangiitis Treatment & Management". Medscape Reference. WebMD. Retrieved 16 March 2014. 
  16. ^ Tarabishy, AB; Schulte, M; Papaliodis, GN; Hoffman, GS (September–October 2010). "Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease.". Survey of Ophthalmology 55 (5): 429–44.  
  17. ^ a b Bosch X, Guilabert A, Espinosa G, Mirapeix E (2007). "Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review". JAMA 298 (6): 655–69.  
  18. ^ Smith, RM; Jones, RB; Jayne, DR (April 2012). "Progress in treatment of ANCA-associated vasculitis." (PDF). Arthritis research & therapy 14 (2): 210.  
  19. ^ a b Cartin-Ceba, R; Peikert, T; Specks, U (December 2012). "Pathogenesis of ANCA-associated vasculitis.". Current Rheumatology Reports 14 (6): 481–93.  
  20. ^ Friedmann I (1982). "McBride and the midfacial granuloma syndrome. (The second 'McBride Lecture', Edinburgh, 1980)". The Journal of laryngology and otology 96 (1): 1–23.  
  21. ^ Fienberg R (1955). "Pathergic granulomatosis". Am. J. Med. 19 (6): 829–31.  
  22. ^ Mendenhall WM, Olivier KR, Lynch JW Jr, Mendenhall NP (2006). "Lethal midline granuloma-nasal natural killer/T-cell lymphoma". Am J Clin Oncol 29 (2): 202–6.  
  23. ^ Woywodt A, Matteson EL (2006). "Wegener's granulomatosis--probing the untold past of the man behind the eponym". Rheumatology (Oxford) 45 (10): 1303–6.  
  24. ^ Woywodt A, Matteson E (2007). "Should eponyms be abandoned? Yes". BMJ 335 (7617): 424.  

References

See also

In 2006, Alexander Woywodt (Preston, United Kingdom) and Eric Matteson (Mayo Clinic, USA) investigated Wegener's past, and discovered that he was, at least at some point of his career, a follower of the Nazi regime. In addition, their data indicate that Wegener was wanted by Polish authorities and that his files were forwarded to the United Nations War Crimes Commission. Furthermore, Wegener worked in close proximity to the genocide machinery in Łódź. Their data raise serious concerns about Wegener's professional conduct. They suggest that the eponym be abandoned and propose "ANCA-associated granulomatous vasculitis."[23] The authors have since campaigned for other medical eponyms to be abandoned, too.[24] In 2011, the American College of Rheumatology (ACR), the American Society of Nephrology (ASN) and the European League Against Rheumatism (EULAR) resolved to change the name to granulomatosis with polyangiitis.[3]

An earlier name for the disease was pathergic granulomatosis.[21] The disease is still sometimes confused with lethal midline granuloma and lymphomatoid granulomatosis, both malignant lymphomas.[22]

Scottish otolaryngologist Peter McBride (1854–1946) first described the condition in 1897 in a BMJ article entitled "Photographs of a case of rapid destruction of the nose and face".[20] Heinz Karl Ernst Klinger (born 1907) would add information on the anatomical pathology, but the full picture was presented by Friedrich Wegener (1907–1990), a German pathologist, in two reports in 1936 and 1939.[2]

History

The incidence is 10-20 cases per million per year.[17][19] It is exceedingly rare in Japan and African Americans.[19]

Epidemiology

Before modern treatments, the 2-year mortality was over 90% and average survival five months.[9][18] Death usually resulted from uremia or respiratory failure.[9]

Today, with corticosteroids and cyclophosphamide, 5-year survival is over 80%.[9] Long-term complications are common (86%), mainly chronic kidney failure, hearing loss and deafness.[1]

Prognosis

  • In generalised non-organ-threatening disease, remission can be induced with methotrexate and steroids, where the steroid dose is reduced after a remission has been achieved and methotrexate used as maintenance.
  • In case of organ-threatening disease, pulsed intravenous cyclophosphamide with steroids is recommended. Once remission has been achieved, azathioprine and steroids can be used to maintain remission.
  • In severe kidney vasculitis, the same regimen is used but with the addition of plasma exchange.
  • In pulmonary haemorrhage, high doses of cyclophosphamide with pulsed methylprednisolone may be used, or alternatively CYC, steroids, and plasma exchange.

[17] The standard treatment for GPA is

Treatment

Several investigators have compared the ACR and Chapel Hill criteria.[14]

According to the Chapel Hill Consensus Conference (CHCC) on the nomenclature of systemic vasculitis (1992), establishing the diagnosis of GPA demands:[13]

  • Nasal or oral inflammation:
    • painful or painless oral ulcers or
    • purulent or bloody nasal discharge
  • Lungs: abnormal chest X-ray with:
    • nodules,
    • infiltrates or
    • cavities
  • Kidneys: urinary sediment with:
  • Biopsy: granulomatous inflammation
    • within the arterial wall or
    • in the perivascular area

In 1990, the American College of Rheumatology accepted classification criteria for GPA. These criteria were not intended for diagnosis, but for inclusion in randomised controlled trials. Two or more positive criteria have a sensitivity of 88.2% and a specificity of 92.0% of describing GPA.[12]

Criteria

If the person has kidney failure or cutaneous vasculitis, a biopsy is obtained from the kidneys. On rare occasions, thoracoscopic lung biopsy is required. On histopathological examination, a biopsy will show leukocytoclastic vasculitis with necrotic changes and granulomatous inflammation (clumps of typically arranged white blood cells) on microscopy. These granulomas are the main reason for the name granulomatosis with polyangiitis, although it is not an essential feature. Nevertheless, necrotizing granulomas are a hallmark of this disease. However, many biopsies can be nonspecific and 50% provide too little information for the diagnosis of GPA.[1]

Granulomatosis with polyangiitis is usually suspected only when a person has had unexplained symptoms for a long period of time. Determination of Anti-neutrophil cytoplasmic antibodies (ANCAs) can aid in the diagnosis, but positivity is not conclusive and negative ANCAs are not sufficient to reject the diagnosis. Cytoplasmic-staining ANCAs that react with the enzyme proteinase 3 (cANCA) in neutrophils (a type of white blood cell) are associated with GPA.[1]

Photo showing the sclerokeratitis associated with GPA
Immunofluorescence pattern produced by binding of ANCA to ethanol-fixed neutrophils, from a person with GPA

Diagnosis

In vitro studies have found that ANCAs can activate neutrophils, increase their adherence to endothelium, and induce their degranulation that can damage endothelial cells. In theory, this phenomenon could cause extensive damage to the vessel wall, in particular of arterioles.[1]

It is now widely presumed that the anti-neutrophil cytoplasmic antibodies (ANCAs) are responsible for the inflammation in GPA.[1] The typical ANCAs in GPA are those that react with proteinase 3, an enzyme prevalent in neutrophil granulocytes.[11]

[1]

This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.